Varespladib's flop: Gene study could have preempted VISTA-16

Results from a Mendelian randomization meta-analysis of 19 general population studies and 10 acute coronary syndrome cohorts suggested varespladib was unlikely to reduce the risk of recurrent cardiovascular events.
Source: theHeart.org - Category: Cardiology Source Type: news